Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Liverpool University to study Dilafor's tafoxiparin for COVID-19

April 17, 2020

CanSino begins phase Ia study of protein-based pneumococcal vaccine

April 17, 2020

Sunshine Lake Pharma discovers HBV HBsAg secretion inhibitors

April 17, 2020

AS-48 shows promising activity in mouse models of Chagas' disease

April 17, 2020

FairJourney and Iontas collaborate in search for SARS-CoV-2 therapy

April 17, 2020

Gilead Sciences begins phase III trial of remdesivir for the treatment of COVID-19 in Japan

April 16, 2020

SPL-7013 demonstrates significant activity against SARS-CoV-2 in lab studies

April 16, 2020

Vir reports interim data from ongoing phase II study of VIR-2218 for chronic HBV infection

April 16, 2020

OncoImmune initiates phase III study with CD24Fc for COVID-19

April 16, 2020

Tocilizumab shows promise in single-center study in patients with COVID-19

April 15, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...